Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 23 04 2023
revised: 07 07 2023
accepted: 11 09 2023
medline: 5 12 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

Renal cell carcinoma (RCC) is a metabolic disease, with subtypes exhibiting aberrations in different metabolic pathways. Metabolomics may offer greater sensitivity for revealing disease biology. We investigated the metabolomic profile of RCC using high-resolution magic angle spinning (HRMAS) proton magnetic resonance spectroscopy ( Surgical tissue samples were obtained from our frozen tissue bank, collected from radical or partial nephrectomy. Specimens were fresh-frozen, then stored at -80 °C until analysis. Tissue HRMAS- Thirty-eight RCC (16 clear cell, 11 papillary, 11 chromophobe), 10 oncocytomas, 7 angiomyolipomas, and 13 adjacent normal tissue specimens (matched pairs) were analyzed. Candidate metabolites for predictors of malignancy based on FDR p-values include histidine, phenylalanine, phosphocholine, serine, phosphocreatine, creatine, glycerophosphocholine, valine, glycine, myo-inositol, scyllo-inositol, taurine, glutamine, spermine, acetoacetate, and lactate. Higher levels of spermine, histidine, and phenylalanine at 3.15 to 3.13 parts per million (ppm) were associated with decreased risk of RCC (OR 4 × 10 HRMAS-

Sections du résumé

BACKGROUND BACKGROUND
Renal cell carcinoma (RCC) is a metabolic disease, with subtypes exhibiting aberrations in different metabolic pathways. Metabolomics may offer greater sensitivity for revealing disease biology. We investigated the metabolomic profile of RCC using high-resolution magic angle spinning (HRMAS) proton magnetic resonance spectroscopy (
METHODS METHODS
Surgical tissue samples were obtained from our frozen tissue bank, collected from radical or partial nephrectomy. Specimens were fresh-frozen, then stored at -80 °C until analysis. Tissue HRMAS-
RESULTS RESULTS
Thirty-eight RCC (16 clear cell, 11 papillary, 11 chromophobe), 10 oncocytomas, 7 angiomyolipomas, and 13 adjacent normal tissue specimens (matched pairs) were analyzed. Candidate metabolites for predictors of malignancy based on FDR p-values include histidine, phenylalanine, phosphocholine, serine, phosphocreatine, creatine, glycerophosphocholine, valine, glycine, myo-inositol, scyllo-inositol, taurine, glutamine, spermine, acetoacetate, and lactate. Higher levels of spermine, histidine, and phenylalanine at 3.15 to 3.13 parts per million (ppm) were associated with decreased risk of RCC (OR 4 × 10
CONCLUSIONS CONCLUSIONS
HRMAS-

Identifiants

pubmed: 37863744
pii: S1078-1439(23)00305-8
doi: 10.1016/j.urolonc.2023.09.005
pii:
doi:

Substances chimiques

Histidine 4QD397987E
Spermine 2FZ7Y3VOQX
Phenylalanine 47E5O17Y3R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

459.e9-459.e16

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interests to declare.

Auteurs

Melissa J Huynh (MJ)

Department of Urology, Massachusetts General Hospital, Boston, MA; Division of Urology, Department of Surgery, Western University, London, Ontario, Canada.

Andrew Gusev (A)

Department of Urology, Massachusetts General Hospital, Boston, MA.

Francesco Palmas (F)

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Lindsey Vandergrift (L)

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Yannick Berker (Y)

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Chin-Lee Wu (CL)

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Shulin Wu (S)

Department of Pathology, Massachusetts General Hospital, Boston, MA.

Leo L Cheng (LL)

Department of Pathology, Massachusetts General Hospital, Boston, MA; Department of Radiology, Massachusetts General Hospital, Boston, MA.

Adam S Feldman (AS)

Department of Urology, Massachusetts General Hospital, Boston, MA. Electronic address: afeldman@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH